Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | TEK | Q02763 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31530943 | 0.82 | NPC1 (0.34) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL25168250 | 0.78 | DGAT1 (0.33) | NPC1DGAT1 | |
| SCHEMBL29991958 | 0.78 | DGAT1 (0.33) | NPC1DGAT1 | |
| SCHEMBL31530983 | 0.78 | DGAT1 (0.35) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL31530698 | 0.78 | NPC1 (0.38) | NPC1DGAT1SRC | |
| SCHEMBL31530985 | 0.77 | DGAT1 (0.36) | NPC1DGAT1 | |
| SCHEMBL28918645 | 0.75 | KDM2B (0.43) | — | |
| SCHEMBL27214805 | 0.75 | EGFR (0.33) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL25407285 | 0.74 | DGAT1 (0.33) | NPC1DGAT1 | |
| SCHEMBL30166560 | 0.74 | DGAT1 (0.33) | NPC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658661-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250345329-A1 | HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF | VORONOI INC (KR) | 2025-11-13 | — | — | US | disclosed |
| EP-4563579-A1 | MACROCYCLIC EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-06-04 | — | — | EP | disclosed |
| CN-119912478-A | Amino heteroaryl macrocyclic compounds, preparation method and application thereof | 北京鞍石生物科技股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4534532-A1 | HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF | Voronoi Inc. (KR) | 2025-04-09 | — | — | EP | disclosed |
| CN-119684317-A | Macrocyclic compound and application thereof | 郑州德迈药业有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119630653-A | Heteroaryl derivative compounds and uses thereof | 株式会社沃若诺伊 | 2025-03-14 | — | — | CN | disclosed |
| WO-2025036453-A1 | EGFR MUTATION INHIBITORS AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2025-02-20 | — | — | WO | disclosed |
| WO-2024177359-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024148932-A1 | EGFR C797S MUTATION INHIBITOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2024-07-18 | — | — | WO | disclosed |
| CN-117865939-A | Aminopyrimidine derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4337665-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Theseus Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117580841-A | Macrocyclic compounds and uses thereof | 特修斯制药公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024022286-A1 | MACROCYCLIC EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| WO-2023229430-A1 | HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF | 보로노이 주식회사 | 2023-11-30 | — | — | WO | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-115551868-A | Macrocyclic compounds and uses thereof | 特修斯制药公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-4107160-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Theseus Pharmaceuticals, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022240978-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | EGFR, ERBB2, ERBB3 | NPC1 670/4885DGAT1 2848/4885EGFR 1/4885 |
| US-20250345329-A1 | HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF | EGFR, ERBB2, ERBB3 | NPC1 703/4885DGAT1 1434/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.